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Highly active transmembrane anion transporters have 
demonstrated their activity against antibiotic-resistant and 
clinically relevant bacterial strains. This type of compounds offers 
promise as strategy to develop novel antibacterial agents. 
The emergence of nosocomial infections caused by multidrug-
resistant (MDR) bacteria is one of the major threats and 
challenges of modern medicine. Resistance has been described 
to nearly all antibiotics currently used in the treatment of 
infectious diseases. ESKAPE acronym encompasses a group of 
pathogens that can develop resistance to many of the most 
used antibiotics and that are frequently involved in hospital-
acquired infections.1 Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa and Enterobacter spp. are included 
in this group. ESKAPE infections are especially worrying in 
intensive care units, where these pathogens represent more 
than 80% of the infections, posing a great threat to the life of 
critically ill and immunocompromised patients.2 Thus, 
developing new antimicrobial agents and strategies to combat 
infections is critical and urgent, both for the treatment of 
patients and also for disinfecting surfaces and medical devices 
in hospital environments, where some pathogens can persist 
even after cleaning, being a significant source for transmission 
of infection to patients.3  
 Small molecules capable of facilitating membrane 
permeation to ions, including for instance polyether 
ionophores and Amphotericin B, constitute relevant examples 
of widely used antimicrobial agents.4 These compounds usually 
promote unspecific or cation selective membrane 
permeability. Membrane-permeabilizing agents have also been 
shown to revert antimicrobial resistance.5-8 Membrane 
disrupting agents such as Polymyxins are used as last resort 
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Fig. 1 Compounds 1-6 and solid state X-Ray structure of 2•HCl 
The antimicrobial activity of anion selective membrane 
ionophores, anionophores,10 remains much less explored, 
although encouraging results including activity against 
methicillin-resistant Staphylococcus aureus (MRSA) have been 
recently reported.11-13 Continuing our efforts to explore the 
biological activity of anionophores inspired in natural 
products,14 herein we describe the antibacterial activity of 
indol-7-yl-decorated tambjamine-like compounds against a 
panel of Gram-positive and Gram-negative bacterial strains as 
well as clinical isolates, including bacterial strains for which the 
World Health Organization consider high or critical the urgency 
of need for new antibiotics.15 
 Compounds 1-6 (Fig. 1) were prepared by condensation of 
7-aminoindole and the appropriate aldehyde in refluxing 
chloroform using acetic acid as catalyst. The compounds were 
isolated as hydrochloric salts and fully characterized 
spectroscopically (see ESI for details). These compounds 
possess a hydrogen bonding cleft defined by four N-H groups 
well suited to interact with anions, as evidenced by data both 
in the solid state and solution. Slow evaporation of a solution 
of 2·HCl in a 1:1 chloroform-methanol mixture provided 
orange single crystals, suitable for X-ray diffraction analysis. In 
the solid state this compound forms a 1:1 supramolecular 
complex with the chloride anion. Its skeleton was found 
essentially flat (torsion angle defined by the four nitrogen 
atoms 9.66°; mean deviation from the plane formed by the 
aromatic rings and those from the imine moiety: 0.06 Å), 
reflecting high electronic delocalization throughout the 
aromatic structure (Fig. 1). The four N-H fragments of the 
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molecule point towards the chloride anion, forming strong 
hydrogen bonds: the N···Cl distances fall in the range 3.09-3.34 
Å, whereas the N-H-Cl angles are close to the ideal value 
(180⁰). 
 Titration experiments of hydroperchloric salts of 
compounds 1-6 in DMSO-d6 allowed us to study and quantify 
anion binding in solution. A representative stack plot of 1H 
NMR spectra is shown in Fig. 2 and the data were fitted with 
Bindfit software (Table 1).16 In order to determine the 
association constants for the chloride adducts it is necessary to 
include a 2:1 (LH:Cl) species (LH being the protonated 
receptor) in the model in all cases, thus suggesting the 
formation of such supramolecular complexes which then lead 
to the 1:1 adduct, a situation previously observed in related 
compounds.17 Dilution experiments involving 1 HCl and 1 
HClO4 indicated the superior binding affinity of this compound 
towards chloride compared with perchlorate, consistent with 
an effective displacement of the latter by chloride in the 
titration experiments of the perchlorate salts with TBACl. 
Under the studied conditions, nitrate was found to be weakly 
coordinating (the displacement of the perchlorate anion is not 
clearly favoured).  
 Transmembrane transport experiments were carried out 
using 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocoline 
liposomes (see ESI for details). Chloride release from chloride 
loaded vesicles was monitored over time with a chloride-
selective electrode.18 At the end of the experiment, a 
detergent was added to lyse the liposomes and the resulting 
chloride reading considered as 100% release of chloride to 
normalize the data. In order to assess the relative potency of 
the carriers, the chloride efflux at 300 seconds for each 
concentration of compound analysed was plotted against such 
concentrations and the resulting curve was fitted using Hill 
analysis. The obtained parameter EC50 represents the 
concentration of transporter needed to induce a 50% chloride 
release at 300 seconds. The lower the EC50 value, the more 
potent the anion carrier is (Table 1). Values well below 
micromolar range were calculated for the EC50 of transporters 
1-4, with compounds 5 and 6 displaying a significantly lower  
 
Fig. 2 Stack plot of partial 1H NMR spectra of compound 2·HClO4 in DMSO-d6:D2O with 
addition of increasing amounts of tetrabutylammonium chloride. 
Table 1. Association constants Ka (M
-1) for compounds 1-6 in their protonated forms 
(1:1 species) with chloride and nitrate (added as tetrabutylammonium salts), 
determined from 1H NMR titration experiments in DMSO-d6 at 293 K and transport 
activities expressed as EC50 (nM). 




1 549 ± 39 – a 16 ± 2 118 ± 4 
2 714 ± 70  8.8 ± 0.7 33 ± 4 896 ± 79 
3 3626 ± 528 21.5 ± 4.6 21 ± 2 666 ± 103 
4 692 ± 52 13.8 ± 1.6 27 ± 2 362 ± 13 
5 834 ± 71 – a 730 ± 102 – 
b 
6 1038 ± 116 1.70 ± 0.1 1511 ± 106 – 
b 
a The association constant value is negligible. b EC50 value could not be 
determined due to precipitation of the compounds at concentrations above 15 
µM. 
activity. These two compounds are more lipophilic than the 
others studied (see ESI Table S2). Being this parameter central 
to determine the activity as carriers of this type of compounds, 
it is possible that their lipophilicity is not optimal to maximize 
their activity.19 The relative variation of EC50  when studying 
chloride efflux in the presence of external nitrate, sulfate or 
bicarbonate is consistent with anion exchange as the main 
mechanism accounting for their transmembrane transport 
activity. Thus, the higher lipophilicity of nitrate compared to 
that of the other anions makes this anion easier to extract in 
the lipid membrane and the calculated EC50 were found 
smaller in the nitrate/chloride exchange than in the 
bicarbonate/chloride exchange assay (Table 1). 
 The antibacterial activity of compounds 1-6 was first 
screened on two Gram-positive (vancomycin-resistant E. 
faecium and methicillin-resistant S. aureus) and two Gram-
negative (A. baumannii and P. aeruginosa) bacterial strains. 
The four of them belong to a group of pathogens with a high 
rate of antibiotic resistance, being responsible for most of 
hospital-acquired infections. Experiments to determine the 
minimum inhibitory concentrations (MICs) were carried out 
(see ESI for details) and the results are displayed in Table 2. 
Overall, the studied compounds were found very effective 
inhibiting the growth of Gram-positive bacteria, especially S. 
aureus, whereas only compound 1 displayed activity against a 
Gram-negative bacterial strain (A. baumannii). The obtained 
results correlate well with the transmembrane transport 
activity of these derivatives. The most potent anionophore 1 
was found the most active antibacterial agent whereas the 
least active anionophore 6 showed the most modest bacterial  
Table 2. Minimum inhibitory concentrations (MICs, µM) for compounds 1-6 against 
different bacterial strains. 
Compound E. faecium S. aureus A. baumannii P. aeruginosa 
1 12.5 5.21 12.5 >100 
2 16.7 8.33 >100 >100 
3 16.7 6.25 >100 >100 
4 25.0 4.16 >100 >100 
5 25.0 8.33 >100 >100 
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Table 3. Minimum inhibitory concentrations (MICs, µM) for compound 1 for different clinical isolates. 
Gram-positive 
ATCC Sa29213 MSSA15 MSSA16 MRSA15 MRSA16 SE14 SE94 
3.125 3.125 3.125 3.125 3.125 3.125 1.56 
MSSA: methicillin-susceptible Staphylococcus aureus; MRSA: methicillin-resistant Staphylococcus aureus; SE: Staphylococcus epidermidis. ATCC Sa29213 was employed 
as quality control. 
Gram-negative 
ATCC EC25922 EC1 EC2 EC3 EC4 EC5 KP1 ATCC Ab19606 AbI1 Ab4249 
6.25 6.25 12.5 12.5 25 6.25 12.5 6.25 3.125 3.125 
Ec: Escherichia coli; Kp: Klebsiella pneumoniae; Ab: Acinetobacter baumannii. ATCC EC25922 and ATCC Ab19606 were employed as quality controls.
inhibition. Likewise, in agreement with previous reports, the 
characteristic additional outer membrane of the Gram- 
negative bacteria represents an effective barrier to prevent 
the inhibitory action of all compounds except the most active 
derivative 1 in these bacteria. 
 The effect of compound 1 on bacterial growth, which 
presented an inhibitory effect in MIC determinations both in 
Gram-negative and Gram-positive bacteria, was studied in A. 
baumannii, S. aureus and E. faecium. For all the species, when 
the growth curve was performed in the presence of 1 at their 
respective MICs (12.5, 5.21 and 12.5 µM for A. baumannii, S. 
aureus and E. faecium, respectively) bacterial growth was 
totally inhibited (Fig. 3). At concentrations below MICs (3.125 
µM) a remarkable growth inhibition was observed in A. 
baumannii and S. aureus. Regarding the latter, a delay of ∼ 17 
hours to reach the logarithmic phase with respect to control 
was noticed, while in A. baumannii this delay was ∼ 8 hours 
(Fig. 3). In the case of E. faecium, this effect was found less 
evident, although the cell density reached was lower than that 
of the control. Overall, these results indicate that compound 1 
can interfere with bacterial growth at concentrations below 
MICs. At the determined MIC, a bactericidal effect against A. 
baumannii was also found (ESI, Figure S116). 
 In light of the promising antibacterial activity displayed by 
compound 1, further experiments were carried out in order to 
assess its activity in both Gram-positive and Gram-negative 
extensively drug-resistant (XDR) clinical isolates. In the case of 
Gram-positive bacteria, different methicillin-susceptible and 
methicillin-resistant S. aureus strains along with S. epidermidis 
clinical strains were employed, whereas for Gram-negative 1 
was screened towards a variety of P. aeruginosa, E. coli, K. 
pneumoniae and A. baumannii strains. The obtained results 
confirmed our previous observations. Compound 1 was found 
effective against all of the tested Gram-positive strains. 
Moreover, good activity against Gram-negative isolates was 
also found, particularly A. baumannii, and also E. coli and K. 
pneumoniae (Table 3). The MICs determined were found lower 
for Gram-positive bacteria than Gram-negative, similarly to our 
previous observations, and no activity was found in the case of 
P. aeruginosa. These results are remarkable since most of 
these bacteria show a high resistance to many of the most 
common antibiotics. The fact that 1 exhibits broad 
antibacterial activity suggests that highly active anion 
transporters could represent a novel class of antimicrobial 
agents displaying novel modes of action effective against 
bacteria which are resistant to conventional antibiotics.  
 We have also studied the interaction of compound 1 with 
blood. Two hemocompatibility tests were performed: a 
hemolysis and a hemagglutination assays. The levels of 
hemoglobin released after 1 hour of incubation in the 
presence of different concentrations of compound 1 are 
displayed in Fig. 4a. Only the highest tested concentration of 1 
(100 µM) showed significant (more than 10%) hemolytic 
activity and at MIC levels hemolytic activity was found to be 
below 5%. This percentage, according to ISO/TR/7406, is 
considered the critical safe hemolytic ratio for biomaterials.20 
This result is in agreement with a lack of detergent effect 
exerted by this compound. Hemagglutination assays were then 
performed. In this assay, the formation of uniform “button-
like” precipitates after incubation is indicative of 
hemocompatibility.21 Compound 1 was serially diluted in 
 
Fig. 3 Growth curves in the presence of compound 1: a) A. baumannii ATCC 17978 
incubated with 12.5 µM (MIC) and 3.125 µM of compound 1; b) S. aureus CECT 5190 
incubated with 5.21 µM (MIC) and 3.125 µM of compound 1; c) E. faecium CECT 5253 
incubated with 12.5 µM (MIC) and 3.125 µM of compound 1. 
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Fig. 4 Hemocompatibility of compound 1: a) hemolysis assay; b) hemagglutination 
assay. 
Dulbecco's Phosphate-Buffered Saline (DPBS) and 100 µL of an 
erythrocyte suspension were added. The results after 12 hours 
of incubation are shown in Fig. 4b. Little differences with 
negative control (PBS buffer) can be seen up to 12.5 µM 
concentrations. Addition of higher concentrations of 
compound 1 or the positive control (Triton-X) resulted in 
altered or no “button-like” precipitate formation. Overall these 
results indicate that compound 1 displays good 
hemocompatibility at concentrations showing significant 
antibacterial activity. 
 In summary, the antibacterial activity of novel indolyl-
decorated tambjamine analogues bearing different 
substitutions on the pyrrole ring attached to the imine moiety 
has been studied. These compounds are highly active 
transmembrane anion transporters being compound 1 the 
most active compound of the series. Antibacterial studies on 
bacterial strains and clinical isolates indicate that 1 possesses 
broad antibacterial activity against both Gram-positive 
bacteria, like E. faecium and S. aureus, and Gram-negative 
bacteria, such as A. baumannii and K. pneumoniae, belonging 
to a group of pathogens that are frequently involved in 
hospital-acquired infections.22 These results support the 
potential of highly active transmembrane anion transporters 
to develop novel antibacterial agents effective against 
antibiotic-resistant bacteria. 
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